S&P 500 Continues Upward Trend Amid Optimism
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy BMY?
Source: CNBC
- Market Performance: The S&P 500 rose again on Friday, and a higher close would mark eight consecutive days of gains, primarily driven by the U.S.-Iran ceasefire news, although the Strait of Hormuz remains partially closed.
- Trading Strategy: Following a more than 18% rise in Broadcom last week, Jim Cramer plans to trim this position on Monday to protect profits and adjust the portfolio's size, adhering to a 72-hour trading rule for compliance.
- Earnings Season Outlook: Next week marks the start of earnings season, with Goldman Sachs set to report before the market opens on Monday, and Jim expects strong results due to market volatility; however, he is less optimistic about Wells Fargo and remains bullish on Johnson & Johnson.
- Rapid Fire Review: In Friday's rapid-fire segment, Jim covered stocks including CoreWeave, CarMax, and Lumentum, emphasizing that subscribers to the CNBC Investing Club will receive trade alerts before any transactions, ensuring transparency and compliance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BMY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BMY
Wall Street analysts forecast BMY stock price to fall
20 Analyst Rating
8 Buy
11 Hold
1 Sell
Moderate Buy
Current: 58.080
Low
37.00
Averages
55.86
High
68.00
Current: 58.080
Low
37.00
Averages
55.86
High
68.00
About BMY
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Bristol-Myers Squibb Listed Among Cash-Rich Dividend Stocks
- Dividend Stock Recommendation: Bristol-Myers Squibb (BMY) is included among 15 cash-rich dividend stocks, indicating its stable cash flow and attractiveness for investors seeking reliable income.
- Analyst Rating Adjustment: BofA analyst Jason Gerberry lowered the price target for BMY from $68 to $67 while maintaining a Buy rating, reflecting a cautious outlook on the company's future performance.
- 2026 Revenue Expectations: The company anticipates revenue between $46 billion and $47.5 billion for 2026, with a projected 12% to 16% decline in its legacy portfolio, although steady performance in its growth portfolio is expected to support overall results.
- Eliquis Sales Outlook: Management expects Eliquis sales to grow by 10% to 15% in 2026, but anticipates a decline of $1.5 billion to $2 billion in 2027 due to patent expirations, highlighting future market challenges.
See More
Analysis of Investment Prospects in Healthcare Stocks
- Animal Health Leader: Zoetis has faced challenges over the past two years, including increased competition and scrutiny over drug side effects; however, its strong market position and the potential market for untreated dogs make it attractive for long-term investors, with expectations to continue launching new products to meet rising pet spending.
- New Drug Development Potential: BioNTech has underperformed in the coronavirus vaccine market, but its impressive pipeline with over 25 clinical trials in oncology, particularly the promising BNT327 developed with Bristol Myers Squibb, could set new standards of care across multiple indications, with significant clinical and regulatory progress expected over the next five years.
- Gene Editing Risks: Intellia Therapeutics' lonvo-z and nex-z are undergoing phase 3 studies but face uncertainty; despite the FDA lifting the hold on clinical trials, the high costs and complexities of gene editing treatments make steady revenue generation unlikely in the coming years, presenting substantial investment risks.
- Dividend Appeal: Zoetis has increased its dividends by 458% over the past decade, making it a top choice for income-seeking investors, reflecting its long-term investment value in the animal health market despite facing short-term challenges.
See More
Strong Performance Fuels Promising Growth Outlook
- Significant Revenue Growth: Johnson & Johnson reported a 9.9% year-over-year revenue increase in Q1, reaching $24.06 billion, surpassing the market expectation of $23.63 billion, which underscores the company's robust performance in pharmaceuticals and medical technology, further solidifying its market position.
- Adjusted EPS Exceeds Expectations: The adjusted earnings per share for the first quarter stood at $2.70, exceeding the anticipated $2.66, reflecting effective management in cost control and profitability, which enhances investor confidence.
- Strong New Drug Sales: Sales of the blood cancer therapy Darzalex rose 22.5% year-over-year to $3.96 billion, exceeding market expectations, while Tremfya sales surged 68% to $1.61 billion, showcasing Johnson & Johnson's competitiveness and market demand in innovative pharmaceuticals.
- Optimistic Future Growth Guidance: Johnson & Johnson raised its full-year guidance, projecting revenue growth between 5.9% and 6.9%, with adjusted EPS expectations increased to a range of $11.45 to $11.65, indicating the company's confidence in future performance and positive market outlook.
See More
Fed Likely to Treat Inflation as One-Off Factors, Says Cramer
- Rate Impact on Market: Jim Cramer highlights that despite escalating geopolitical tensions, the S&P 500 has recently rebounded to within 1.5% of its all-time high due to sustained low interest rates, indicating a strong market resilience.
- Oil Prices and Inflation: Cramer argues that while oil prices have surged due to supply disruptions in the Strait of Hormuz, their broader economic impact may be less pronounced than in past energy shocks, as modern vehicles are more fuel-efficient and natural gas remains relatively cheap domestically.
- Fed Policy Outlook: Cramer predicts that with interest rates stabilizing, the Fed is unlikely to raise short-term rates and may even consider rate cuts, which would further support stock valuations and investor confidence.
- Market Resilience: Cramer emphasizes that the market's ability to overlook geopolitical events and focus on fundamentals, particularly interest rates, is crucial, as evidenced by strong performances from software stocks like Salesforce and Microsoft, contrasting with lagging energy stocks.
See More
Market Resilience Driven by Interest Rates Amid Geopolitical Tensions
- Interest Rate Impact: Cramer highlights that despite escalating geopolitical tensions, low interest rates are the key driver behind the stock market's rebound, with the S&P 500 rising back to within 1.5% of its all-time high, even amid surging oil prices.
- Oil Prices and Inflation: While oil prices have surged due to supply disruptions in the Strait of Hormuz, Cramer argues that their broader economic impact is less pronounced than in past energy shocks, thanks to improved vehicle fuel efficiency and lower domestic natural gas prices, which mitigate inflationary pressures.
- Fed Policy Outlook: Cramer notes that as interest rates have rolled over, the new Federal Reserve chair may not raise short-term rates and could even consider rate cuts, further supporting high stock valuations in the market.
- Focus on Fundamentals: Cramer emphasizes that investors should concentrate on the impact of interest rates on stock prices rather than geopolitical events, as evidenced by Monday's trading where beaten-down software stocks like Salesforce and Microsoft outperformed the lagging energy sector.
See More
Bristol Myers Squibb: A New Value Investment Choice
- Valuation Appeal: Bristol Myers Squibb's forward P/E ratio of approximately 9.5 makes it an attractive value stock compared to competitors like Johnson & Johnson and Merck, which have ratios of 21 and 24, potentially drawing interest from value-focused investors.
- Stable Dividend Yield: With a dividend yield of 4.2% and a history of 94 consecutive years of dividend payments, including 17 years of increases, the company demonstrates strong cash flow and commitment to shareholders, bolstering investor confidence.
- Revenue Growth Potential: While revenue for 2024 and 2025 is projected at $48.3 billion and $48.2 billion respectively, with a decline expected in 2026 to between $46 billion and $47.5 billion, the growth portfolio's revenue increased from $22.6 billion to $26.4 billion, indicating strong potential in new drug development.
- Acquisition Strategy: The planned $1.5 billion acquisition of Orbital Therapeutics, despite the existing $47 billion debt, could enhance Bristol's pipeline and help mitigate revenue losses from upcoming patent cliffs, showcasing a strategic vision for long-term growth.
See More
Bristol-Myers Squibb Listed Among Cash-Rich Dividend Stocks
- Dividend Stock Recommendation: Bristol-Myers Squibb (BMY) is included among 15 cash-rich dividend stocks, indicating its stable cash flow and attractiveness for investors seeking reliable income.
- Analyst Rating Adjustment: BofA analyst Jason Gerberry lowered the price target for BMY from $68 to $67 while maintaining a Buy rating, reflecting a cautious outlook on the company's future performance.
- 2026 Revenue Expectations: The company anticipates revenue between $46 billion and $47.5 billion for 2026, with a projected 12% to 16% decline in its legacy portfolio, although steady performance in its growth portfolio is expected to support overall results.
- Eliquis Sales Outlook: Management expects Eliquis sales to grow by 10% to 15% in 2026, but anticipates a decline of $1.5 billion to $2 billion in 2027 due to patent expirations, highlighting future market challenges.
See More
Analysis of Investment Prospects in Healthcare Stocks
- Animal Health Leader: Zoetis has faced challenges over the past two years, including increased competition and scrutiny over drug side effects; however, its strong market position and the potential market for untreated dogs make it attractive for long-term investors, with expectations to continue launching new products to meet rising pet spending.
- New Drug Development Potential: BioNTech has underperformed in the coronavirus vaccine market, but its impressive pipeline with over 25 clinical trials in oncology, particularly the promising BNT327 developed with Bristol Myers Squibb, could set new standards of care across multiple indications, with significant clinical and regulatory progress expected over the next five years.
- Gene Editing Risks: Intellia Therapeutics' lonvo-z and nex-z are undergoing phase 3 studies but face uncertainty; despite the FDA lifting the hold on clinical trials, the high costs and complexities of gene editing treatments make steady revenue generation unlikely in the coming years, presenting substantial investment risks.
- Dividend Appeal: Zoetis has increased its dividends by 458% over the past decade, making it a top choice for income-seeking investors, reflecting its long-term investment value in the animal health market despite facing short-term challenges.
See More
Strong Performance Fuels Promising Growth Outlook
- Significant Revenue Growth: Johnson & Johnson reported a 9.9% year-over-year revenue increase in Q1, reaching $24.06 billion, surpassing the market expectation of $23.63 billion, which underscores the company's robust performance in pharmaceuticals and medical technology, further solidifying its market position.
- Adjusted EPS Exceeds Expectations: The adjusted earnings per share for the first quarter stood at $2.70, exceeding the anticipated $2.66, reflecting effective management in cost control and profitability, which enhances investor confidence.
- Strong New Drug Sales: Sales of the blood cancer therapy Darzalex rose 22.5% year-over-year to $3.96 billion, exceeding market expectations, while Tremfya sales surged 68% to $1.61 billion, showcasing Johnson & Johnson's competitiveness and market demand in innovative pharmaceuticals.
- Optimistic Future Growth Guidance: Johnson & Johnson raised its full-year guidance, projecting revenue growth between 5.9% and 6.9%, with adjusted EPS expectations increased to a range of $11.45 to $11.65, indicating the company's confidence in future performance and positive market outlook.
See More
Fed Likely to Treat Inflation as One-Off Factors, Says Cramer
- Rate Impact on Market: Jim Cramer highlights that despite escalating geopolitical tensions, the S&P 500 has recently rebounded to within 1.5% of its all-time high due to sustained low interest rates, indicating a strong market resilience.
- Oil Prices and Inflation: Cramer argues that while oil prices have surged due to supply disruptions in the Strait of Hormuz, their broader economic impact may be less pronounced than in past energy shocks, as modern vehicles are more fuel-efficient and natural gas remains relatively cheap domestically.
- Fed Policy Outlook: Cramer predicts that with interest rates stabilizing, the Fed is unlikely to raise short-term rates and may even consider rate cuts, which would further support stock valuations and investor confidence.
- Market Resilience: Cramer emphasizes that the market's ability to overlook geopolitical events and focus on fundamentals, particularly interest rates, is crucial, as evidenced by strong performances from software stocks like Salesforce and Microsoft, contrasting with lagging energy stocks.
See More
Market Resilience Driven by Interest Rates Amid Geopolitical Tensions
- Interest Rate Impact: Cramer highlights that despite escalating geopolitical tensions, low interest rates are the key driver behind the stock market's rebound, with the S&P 500 rising back to within 1.5% of its all-time high, even amid surging oil prices.
- Oil Prices and Inflation: While oil prices have surged due to supply disruptions in the Strait of Hormuz, Cramer argues that their broader economic impact is less pronounced than in past energy shocks, thanks to improved vehicle fuel efficiency and lower domestic natural gas prices, which mitigate inflationary pressures.
- Fed Policy Outlook: Cramer notes that as interest rates have rolled over, the new Federal Reserve chair may not raise short-term rates and could even consider rate cuts, further supporting high stock valuations in the market.
- Focus on Fundamentals: Cramer emphasizes that investors should concentrate on the impact of interest rates on stock prices rather than geopolitical events, as evidenced by Monday's trading where beaten-down software stocks like Salesforce and Microsoft outperformed the lagging energy sector.
See More
Bristol Myers Squibb: A New Value Investment Choice
- Valuation Appeal: Bristol Myers Squibb's forward P/E ratio of approximately 9.5 makes it an attractive value stock compared to competitors like Johnson & Johnson and Merck, which have ratios of 21 and 24, potentially drawing interest from value-focused investors.
- Stable Dividend Yield: With a dividend yield of 4.2% and a history of 94 consecutive years of dividend payments, including 17 years of increases, the company demonstrates strong cash flow and commitment to shareholders, bolstering investor confidence.
- Revenue Growth Potential: While revenue for 2024 and 2025 is projected at $48.3 billion and $48.2 billion respectively, with a decline expected in 2026 to between $46 billion and $47.5 billion, the growth portfolio's revenue increased from $22.6 billion to $26.4 billion, indicating strong potential in new drug development.
- Acquisition Strategy: The planned $1.5 billion acquisition of Orbital Therapeutics, despite the existing $47 billion debt, could enhance Bristol's pipeline and help mitigate revenue losses from upcoming patent cliffs, showcasing a strategic vision for long-term growth.
See More
